CLDN18.2蛋白在恶性肿瘤治疗中的研究进展  

Advances of CLDN18.2 protein in the therapy of malignant tumors

作　　者：徐良额 何天阳 张丽[1] 陆一丹[1] 罗聪[3] Liang-e Xu;Tianyang He;Li Zhang;Yidan Lu;Cong Luo(Zhejiang Chinese Medical University,Hangzhou 310053,China;Tiantai People's Hospital of Zhejiang Province,Taizhou 317200,China;Department of Abdominal Oncology,Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学,杭州市310053 [2]天台县人民医院 [3]浙江省肿瘤医院腹部肿瘤内科

出　　处：《中国肿瘤临床》2019年第6期311-315,共5页Chinese Journal of Clinical Oncology

基　　金：浙江省自然科学基金(编号:LY15H160003)资助~~

摘　　要：随着分子生物学研究的进展,靶向治疗已成为除手术、放疗、化疗之外恶性肿瘤治疗中的第四种有效手段。与传统化疗药物不同,分子靶向治疗药物具有特异性强、疗效明显、不良反应较小等优点。CLDN18.2蛋白是新发现的一种跨膜蛋白,具有高选择性特点,稳定地过表达于多种恶性肿瘤中,尤其是消化系统肿瘤及其转移瘤。近年来,其特异性抗体claudiximab(zolbetuximab/IMAB362)在最新的临床试验中取得了显著的成功,CLDN18.2蛋白有望成为某些特定恶性肿瘤靶向治疗的分子靶点。With the development of molecular biology research,targeted therapy has become the fourth effective method for the treatment of malignant tumors after surgery,radiotherapy,and chemotherapy.Unlike the traditional chemotherapeutic drugs,molecular targeted drugs possess the advantages of high specificity,definite curative effects,and less adverse effects.CLDN18.2 protein is a transmembrane protein that is highly selective and stably overexpressed during the development of various malignant tumors,especially gastrointestinal tumors,and metastases.A specific antibody against this protein,claudiximab(zolbetuximab/IMAB362),has achieved great success in recent clinical trials.Thus,CLDN18.2 protein is expected to be a safe and effective molecular target for targeted therapy in some malignancies.

关 键 词：CLDN18.2 恶性肿瘤 靶向治疗 claudiximab(zolbetuximab/IMAB362) 

分 类 号：R730.5[医药卫生—肿瘤]